Tishtha Nivolumab 40mg Injection

Tishtha Nivolumab 40mg Injection works by targeting the PD-1/PD-L1 pathway. Many cancer cells use this pathway to “turn off” the immune system’s T-cells, allowing the tumor to grow unchecked. By blocking the PD-1 receptor, Nivolumab reactivates these T-cells, enabling them to seek out and eliminate cancer cells throughout the body. This mechanism often leads to long-term remission in patients who have not responded to traditional chemotherapy.

Key Clinical Benefits of Tishtha

• Broad-Spectrum Efficacy: Effective against a wide range of solid tumors and hematological malignancies.

• Improved Survival Rates: Proven to extend progression-free survival and overall survival in metastatic cancer patients.

• Zydus Quality Standards: Produced by Zydus, a global leader in biosimilar development, ensuring that Tishtha meets rigorous safety and purity benchmarks.

• Combination Potential: Frequently used in combination with other immunotherapies or targeted drugs to maximize tumor shrinkage.

Administration & Safety Protocols

1. Infusion Method: Administered as an Intravenous (IV) infusion over 30 to 60 minutes.

2. Dosing Schedule: Usually given every 2, 3, or 4 weeks, depending on the specific cancer type and the oncologist’s protocol.

3. Temperature Control: Must be refrigerated at 2°C to 8°C. Do not freeze or shake the vial.

4. Monitoring: Patients must be monitored for immune-related adverse events (irAEs), where the immune system may attack healthy organs like the lungs, liver, or colon.

Frequently Asked Questions (FAQs)

1. Is Tishtha the same as Opdivo? Yes. Tishtha is a high-quality version containing Nivolumab, the same active ingredient found in Opdivo. It is used for the same clinical indications and offers a more cost-effective option for immunotherapy.

2. What types of cancer does Nivolumab treat? Nivolumab is FDA and globally approved for advanced melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma (RCC), classical Hodgkin lymphoma, and squamous cell carcinoma of the head and neck.

3. Does Milan Medicals ship Tishtha to the UAE and USA? Yes. We specialize in the international distribution of biologics. We use medical-grade, validated cold-chain packaging with temperature monitors to ensure Tishtha 40mg arrives safely in the USA, UAE, KSA, UK, and Europe.

4. How long does it take to see results with Tishtha? Immunotherapy works differently than chemotherapy. Some patients see tumor shrinkage within 2–3 months, while others may experience “pseudoprogression” (temporary tumor swelling) before the cancer begins to recede.

5. What are the side effects of Nivolumab? Common side effects include fatigue, rash, and musculoskeletal pain. Because it stimulates the immune system, it can cause inflammation in healthy organs (immune-mediated side effects). Any new cough, diarrhea, or severe skin rash should be reported to a doctor immediately.